// App-Quantinova.ai

SAT0155 : WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN MTX-NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) (FINCH3)

Researchers

Presenter

  • P. C. Taylor

Principal Investigators

  • B. Downie

  • E. Elboudwarej

  • S. Kim

  • A. Hertz

  • A. M. Mirza

  • J. Siegel

  • R. E. Hawtin

  • J. Liu

Medical Centers

  • University of Oxford, Botnar Research Centre, Nuffield Dept Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Gilead Sciences Inc, Foster City, United States of America, Foster City, CA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02886728

Sponsors

  • Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved